Dossier assessment
Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Routine prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) with FVIII inhibitors and of 12 years of age or more
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-10-16 A G-BA decision was published.
Project details
- Project no.
- A25-55
- Commission
- Commission awarded on 29.04.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-55_en
Connected Projects
-
Dossier assessment
Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Concizumab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Concizumab (haemophilia A, haemophilia B) – Addendum to Projects A25-55 and A25-56
Status: Commission completed
-
Dossier assessment
Concizumab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed